Research with a destination | A question to investigate
The people affected should help shape the question.
Medicines research can become more relevant when the people who live with its consequences influence its design. We want to develop partnerships that give public perspectives a clear role before a protocol, product story or discovery experience becomes fixed.
Ask what the original question leaves out.
A research team may define a problem through available data, a scientific mechanism or an operational pressure. People receiving care may recognise a different difficulty: confusing information, repeated explanations or a burden that the proposed outcome does not capture. We propose examining those differences early. Public involvement should help determine which questions deserve attention and what a useful result would mean, rather than serve only as a favourable quote after the design is complete.
Be clear about the kind of involvement.
The HRA distinguishes involvement in research design from participation in a study (Health Research Authority, n.d.). That distinction matters for an honest invitation. A person helping review a proposed question is not automatically consenting to become a research participant, share clinical information or endorse a technology. The first partnership would establish the role, time commitment, support and influence available to contributors, with clear information about what is being developed and what decisions remain open.
Include the people a convenient panel might miss.
Recruiting only confident, available voices can narrow the view of a medicines problem. We would discuss whose perspectives are missing and which barriers affect involvement, such as timing, language, accessibility or previous experiences of research. The appropriate approach would depend on the project and community. A small initial group could identify useful issues, but we would not present it as representative of everyone affected or use personal stories as proof of widespread demand.
Let contribution alter the design.
A proposed workshop could test a research question, a draft explanation or a set of candidate outcomes. The useful output would record what changed because of the discussion, what could not change and why. Academic and professional collaborators would retain responsibility for scientific and ethical decisions while explaining their reasoning. Public contributors should be able to see the consequence of their work rather than being left with a polished summary that ignores the difficult points they raised.
A public decision brief | An illustrative example
Open the question.
Inspect the reasoning.
Choose a business question, then look beneath its claim. See what a public source supports, what depends on the local setting and what a useful next step could be.
An academic or development team examining the next experiment after a published model comparison.
What does this result allow us to ask next?
A promising figure can sharpen a research question. Its value depends on keeping the model, observation and next hypothesis distinct.
A proposition to investigate
A clearer question can be a useful output.
An evidence brief could help a team distinguish a published observation from the experiment needed to investigate translation. The proposed value is a more precise comparison and an explicit evidence gap. It does not turn an external model result into a clinical claim or a NEUVIOR discovery.
This is a constructed research-planning question, not an agreed study or product-development result.
What the next brief would contain
A decision someone
can commission.
- The decision
- Whether a specific follow-on question has a credible experimental comparison.
- The comparator
- A scientifically justified model or condition relevant to the proposed hypothesis.
- The evidence
- Full methods, model relevance, measurements, replication and a feasible authorised protocol.
- Stop or redesign
- Stop or redesign if the proposed model cannot answer the question or the required work is not feasible.
Constructed public example | Not PHARMORIS-generated software output or a measured customer result.
Keep this example briefCompare the design before and after involvement.
Evaluation might examine whether contributors identified missing burdens, clarified confusing materials or changed the relevance of a proposed outcome. It should not reduce involvement to attendance or satisfaction alone. We would compare successive versions of the research materials and document decisions. Where appropriate, independent reviewers could examine whether the changes improved clarity or feasibility. The result would be an account of influence, including disagreement and limitations, rather than a claim that involvement guarantees better outcomes.
Link discovery with a route back into research.
UKRI's public-engagement resources provide context for exchange between research and society (UKRI, n.d.). The planned Constellation public-discovery concept could eventually offer one setting for that exchange, alongside other formats. It is an ambition, not an operating museum or recruitment service. A discovery event, an involvement group and a formal study have different purposes and permissions. We want those connections to be meaningful without blurring participation, promotion and research governance.
Begin with a question people can genuinely change.
The bounded first step is a supported discussion around one proposed research question or set of materials, with an agreed decision owner and a feedback plan. Continuation would depend on a clear contribution to the design and an acceptable experience for contributors. We would pause if the decisions are already closed, if participation creates unsupported burdens or if the organisation cannot explain how input will be used. The invitation should offer influence that the project can honour.
Sources and context
Health Research Authority (n.d.) Public involvement. Available at: https://www.hra.nhs.uk/planning-and-improving-research/best-practice/public-involvement/ (Accessed: 14 October 2026).
UKRI (n.d.) Public engagement. Available at: https://www.ukri.org/what-we-do/public-engagement/ (Accessed: 14 October 2026).
Another useful angle.
- Evidence review quality
Explore a proposed medicines evidence study comparing source fidelity, review quality and total checking effort, with a clear decision for research partners.
- Reproducible medicines analysis
Explore reproducible medicines analysis that connects source data, calculation and interpretation, giving research partners a result they can check and update.
- Academic and commercial translation
Connect an academic finding with a credible user, comparator and next experiment, while keeping research rights and commercial translation questions clear.
